Skip to content
Biotechnology

BTC announces CFO and Company Secretary appointment

BTC Health Limited (ASX:BTC) 2 mins read

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment of Salesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025. This appointment reflects the underlying expansion of the BTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from 17 March 2025.

Salesh joins BTC from Universal Biosensors Australia, where he was the Chief Financial Officer and Company Secretary for more than 18 years. He is a member of the Institute of Chartered Accountants, (CA) and Certified Practicing Accountants (CPA).

BTC’s current Company Secretary, Tracy Weimar, will remain in place through 16 March 2025 and resign to coincide with Salesh's appointment. For the purposes of ASX Listing Rule 12.6, Salesh will be responsible for communications between the Company and ASX from 17 March 2025.

BTC Health Executive Chairman Dr Richard Treagus said, “I am delighted to welcome Salesh to BTC. He brings significant international experience applicable to high-growth companies in the healthcare and medical sectors. He joins us at an exciting time in BTC’s growth journey and he will be a valuable addition to the leadership team.


About us:

About BTC Health
BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:

- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.


Contact details:

For more information, please contact:

BTC Health Limited (ASX:BTC)
Dr Richard Treagus 
Executive Director
T:  +61 417 520 509 
E: [email protected]

Tracy Weimar
Company Secretary
T: +61 3 9692 7222
E: t[email protected]

Investor Relations
The Capital Network 
Julia Maguire
T: +61 2 7257 7338
E: [email protected]

More from this category

  • Biotechnology
  • 12/06/2025
  • 11:26
CLEO DIAGNOSTICS LTD

Corporate Presentation June 2025

Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company’s strategy and progress on “Pioneering the Transformation of Ovarian Cancer Detection.” The…

  • Contains:
  • Biotechnology, Environment
  • 05/06/2025
  • 12:13
EcoPHA

Australia’s New Green Alliance: How Pongamia Trees and PHA Are Powering a Cleaner Future

June 2025 – Australia As global industry races to decarbonise, an unlikely hero is emerging from the Australian landscape: the pongamia tree. Recently highlighted in Rio Tinto’s ambitious biofuels project, this native species is now at the centre of a broader movement, one that includes sustainable bioplastics, climate-resilient agriculture, and nature-based solutions to emissions reduction. Australia's very own leading biotech firm, EcoPHAis proud to announce its integrated pongamia plantation and bioplastic initiative - linking reforestation,biofuel, and bioplastic innovation into a single circular economy model. While Rio Tinto’s planting of 750,000 pongamia trees near Townsville marks a bold step toward renewable…

  • Biotechnology, Medical Health Aged Care
  • 02/06/2025
  • 11:54
INOVIQ Limited

EARLY OVARIAN CANCER SCREENING BREAKTHROUGH

INOVIQ Limited (ASX: IIQ) is pleased to announce game-changing results from its EXO-OC™ ovarian cancer test presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2025 in Chicago. The Poster titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test is copied below. The test uses proprietary technology to isolate exosomes and combines multiple exosomal biomarkers in an AI-enhanced algorithm to enable the early and accurate detection of ovarian cancer. Since reporting high level results from a biomarker study validating protein biomarkers on 3 December 2024, INOVIQ worked with one of Australia’s most…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.